Dassault Systèmes stock gains visibility from Medidata award

Medidata, a Dassault Systèmes brand, said on Tuesday, November 10, 2026, that its Synthetic Control Arm had won the Real World Evidence Solution of the Year award at the sixth annual BioTech Breakthrough Awards. The company announcement said the award was selected from 1,500 entries across life sciences and biotechnology.

The recognition concerns a technology designed to replace or supplement conventional randomized control groups in clinical trials. According to Medidata, the external control arm uses aggregated, anonymized patient-level information from more than 42,000 clinical trials and 13 million patients. Propensity-score modelling is used to match the characteristics of a study population.

Clinical-trial design drives recognition

Medidata said its Synthetic Control Arm can help sponsors reduce the need for placebo or standard-of-care groups, particularly in rare diseases and studies where eligible patients are limited. The approach is intended to ease recruitment pressure while giving more participants access to investigational treatments.

The company cited a partnership with immunotherapy developer Medicenna in which Medidata negotiated a hybrid external control arm design with the U.S. Food and Drug Administration. The design reduced the required randomized control arm in a Phase 3 trial by 66%, according to the announcement.

Medidata also highlighted work with CAR T-cell company Autolus. Its external control arm was used to contextualize a single-arm Phase 2 study of Aucatzyl in B-cell precursor acute lymphoblastic leukemia. Medidata said the analysis contributed to a broader assessment alongside the pivotal trial results.

Visibility rises without target change

Anthony Costello, Medidata's chief executive, said the award recognized the use of artificial intelligence to generate scientifically rigorous evidence, reduce the burden on patients and sites, and support regulatory approvals. The announcement did not change Dassault Systèmes' financial targets.

Dassault Systèmes stock traded at 25.40 euros on Lang & Schwarz at 10:39 CET on Thursday, November 12, 2026. The quote puts the stock's life-sciences exposure in focus, although the award itself is not a new financial forecast.

The European market backdrop provides the wider setting for investors following technology and healthcare software shares.

More news and analyses on Dassault Systèmes stock.